{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T23:00:03Z","timestamp":1784156403819,"version":"3.55.0"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,3]],"date-time":"2026-01-03T00:00:00Z","timestamp":1767398400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T00:00:00Z","timestamp":1769990400000},"content-version":"vor","delay-in-days":30,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Pulm Med"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>For patients with chronic thromboembolic pulmonary hypertension (CTEPH), balloon pulmonary angioplasty (BPA) has been associated with superior reductions in mean pulmonary artery pressure (mPAP) and pulmonary vascular resistance (PVR) when compared to riociguat. In patients with pulmonary arterial hypertension (PAH), greater clinical improvements were observed after switching from phosphodiesterase-5 inhibitors (PDE5i) to riociguat. However, the impact of transitioning from PDE5i to riociguat on pulmonary haemodynamics and functional outcomes after BPA remains unclear.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This prospective, open-label, single-arm, study enrolled CTEPH patients who remained symptomatic following BPA. After a 24-hour PDE5i washout period, patients were switched to riociguat. At week 26, primary outcomes assessed changes in haemodynamics including PVR and mPAP. Secondary endpoints evaluated cardiac index; functional status including WHO functional class, 6-minute walking distance (6MWD), REVEAL Lite 2 score; biochemical markers such as N-terminal prohormone of brain natriuretic peptide (NT-proBNP); and echocardiographic measurements of right-heart function. Treatment-related adverse events and clinical worsening were monitored throughout the study.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      From July 2024 to January 2025, 16 patients (mean age 62.3\u2009\u00b1\u200914.6 years; 75% female) were recruited, with 14 completing the 26-week follow-up. At week 26, significant reductions occurred in PVR (-2.16 Wood units; CI -3.64 to -0.69;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.007) and mPAP (-4.79 mmHg; Confidence Interval [CI] -8.05 to -1.52;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.007). Significant improvements were also noted in cardiac index, WHO functional class, 6MWD, REVEAL Lite 2 score and NT-proBNP levels. Echocardiographic measurements of right-heart function did not demonstrate significant improvement. Treatment-related adverse events were observed in 11 patients (68.75%). Clinical worsening occurred in four patients, including two deaths unrelated to treatment and two unplanned hospitalisations due to pulmonary hypertension.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>In CTEPH patients after completion of BPA, replacing PDE5i with riociguat significantly enhanced pulmonary haemodynamics and functional capacity but was accompanied by a considerable risk of treatment-related adverse events.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration<\/jats:title>\n                    <jats:p>ClinicalTrials.gov Identifier NCT06715280 retrospectively registered on 26\/11\/2024.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12890-025-04069-y","type":"journal-article","created":{"date-parts":[[2026,1,3]],"date-time":"2026-01-03T09:42:44Z","timestamp":1767433364000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Haemodynamic and clinical impacts of switching phosphodiesterase-5 inhibitors to riociguat in patients with chronic thromboembolic pulmonary hypertension (CTEPH) after balloon pulmonary angioplasty (BPA) \u2013 a prospective cohort study"],"prefix":"10.1186","volume":"26","author":[{"given":"Timothy Ho Him","family":"Kam","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin Ka Ho","family":"Kam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael Ka Lam","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bryan Ping Yen","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guangming","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,3]]},"reference":[{"issue":"1","key":"4069_CR1","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.athoracsur.2012.04.004","volume":"94","author":"MM Madani","year":"2012","unstructured":"Madani MM, Auger WR, Pretorius V, Sakakibara N, Kerr KM, Kim NH, et al. Pulmonary endarterectomy: recent changes in a single institution\u2019s experience of more than 2,700 patients. Ann Thorac Surg. 2012;94(1):97\u2013103.","journal-title":"Ann Thorac Surg"},{"issue":"3","key":"4069_CR2","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1016\/j.jtcvs.2010.11.024","volume":"141","author":"E Mayer","year":"2011","unstructured":"Mayer E, Jenkins D, Lindner J, D\u2019armini A, Kloek J, Meyns B, et al. Surgical management and outcome of patients with chronic thromboembolic pulmonary hypertension: results from an international prospective registry. J Thorac Cardiovasc Surg. 2011;141(3):702\u201310.","journal-title":"J Thorac Cardiovasc Surg"},{"issue":"38","key":"4069_CR3","doi-asserted-by":"publisher","first-page":"3618","DOI":"10.1093\/eurheartj\/ehac237","volume":"43","author":"M Humbert","year":"2022","unstructured":"Humbert M, Kovacs G, Hoeper MM, Badagliacca R, Berger RMF, Brida M, et al. 2022 ESC\/ERS guidelines for the diagnosis and treatment of pulmonary hypertension: developed by the task force for the diagnosis and treatment of pulmonary hypertension of the European society of cardiology (ESC) and the European respiratory society (ERS). Endorsed by the international society for heart and lung transplantation (ISHLT) and the European reference network on rare respiratory diseases (ERN-LUNG). Eur Heart J. 2022;43(38):3618\u2013731.","journal-title":"Eur Heart J"},{"issue":"4","key":"4069_CR4","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1056\/NEJMoa1209657","volume":"369","author":"H-A Ghofrani","year":"2013","unstructured":"Ghofrani H-A, D\u2019Armini AM, Grimminger F, Hoeper MM, Jansa P, Kim NH, et al. Riociguat for the treatment of chronic thromboembolic pulmonary hypertension. N Engl J Med. 2013;369(4):319\u201329.","journal-title":"N Engl J Med"},{"issue":"6","key":"4069_CR5","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1016\/S2213-2600(20)30532-4","volume":"9","author":"MM Hoeper","year":"2021","unstructured":"Hoeper MM, Al-Hiti H, Benza RL, Chang S-A, Corris PA, Gibbs JSR, et al. Switching to Riociguat versus maintenance therapy with phosphodiesterase-5 inhibitors in patients with pulmonary arterial hypertension (REPLACE): a multicentre, open-label, randomised controlled trial. Lancet Respiratory Med. 2021;9(6):573\u201384.","journal-title":"Lancet Respiratory Med"},{"key":"4069_CR6","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.02425-2016","author":"MM Hoeper","year":"2017","unstructured":"Hoeper MM, Simonneau G, Corris PA, Ghofrani H-A, Klinger JR, Langleben D, et al. Respite: switching to riociguat in pulmonary arterial hypertension patients with inadequate response to phosphodiesterase-5 inhibitors. Eur Respir J. 2017. https:\/\/doi.org\/10.1183\/13993003.02425-2016.","journal-title":"Eur Respir J"},{"issue":"4","key":"4069_CR7","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1016\/j.resinv.2017.04.004","volume":"55","author":"K Yamamoto","year":"2017","unstructured":"Yamamoto K, Tanabe N, Suda R, Sasaki A, Matsumura A, Ema R, et al. Riociguat for patients with chronic thromboembolic pulmonary hypertension: usefulness of transitioning from phosphodiesterase type 5 inhibitor. Respir Investig. 2017;55(4):270\u20135.","journal-title":"Respir Investig"},{"key":"4069_CR8","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.02828-2020","author":"M Delcroix","year":"2021","unstructured":"Delcroix M, Torbicki A, Gopalan D, Sitbon O, Klok FA, Lang I, et al. ERS statement on chronic thromboembolic pulmonary hypertension. Eur Respir J. 2021. https:\/\/doi.org\/10.1183\/13993003.02828-2020.","journal-title":"Eur Respir J"},{"issue":"10","key":"4069_CR9","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1016\/S2213-2600(22)00171-0","volume":"10","author":"T Kawakami","year":"2022","unstructured":"Kawakami T, Matsubara H, Shinke T, Abe K, Kohsaka S, Hosokawa K, et al. Balloon pulmonary angioplasty versus riociguat in inoperable chronic thromboembolic pulmonary hypertension (MR BPA): an open-label, randomised controlled trial. Lancet Respir Med. 2022;10(10):949\u201360.","journal-title":"Lancet Respir Med"},{"issue":"10","key":"4069_CR10","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1016\/S2213-2600(22)00214-4","volume":"10","author":"X Ja\u00efs","year":"2022","unstructured":"Ja\u00efs X, Brenot P, Bouvaist H, Jevnikar M, Canuet M, Chabanne C, et al. Balloon pulmonary angioplasty versus riociguat for the treatment of inoperable chronic thromboembolic pulmonary hypertension (RACE): a multicentre, phase 3, open-label, randomised controlled trial and ancillary follow-up study. Lancet Respir Med. 2022;10(10):961\u201371.","journal-title":"Lancet Respir Med"},{"issue":"4","key":"4069_CR11","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1056\/NEJM199507273330403","volume":"333","author":"A Giaid","year":"1995","unstructured":"Giaid A, Saleh D. Reduced expression of endothelial nitric oxide synthase in the lungs of patients with pulmonary hypertension. N Engl J Med. 1995;333(4):214\u201321.","journal-title":"N Engl J Med"},{"issue":"2","key":"4069_CR12","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1183\/09031936.00049312","volume":"41","author":"IM Lang","year":"2013","unstructured":"Lang IM, Pesavento R, Bonderman D, Yuan JX. Risk factors and basic mechanisms of chronic thromboembolic pulmonary hypertension: a current understanding. Eur Respir J. 2013;41(2):462\u20138.","journal-title":"Eur Respir J"},{"issue":"3","key":"4069_CR13","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1378\/chest.103.3.685","volume":"103","author":"KM Moser","year":"1993","unstructured":"Moser KM, Bioor CM. Pulmonary vascular lesions occurring in patients with chronic major vessel thromboembolic pulmonary hypertension. Chest. 1993;103(3):685\u201392.","journal-title":"Chest"},{"issue":"2","key":"4069_CR14","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1378\/chest.07-2681","volume":"134","author":"J Suntharalingam","year":"2008","unstructured":"Suntharalingam J, Treacy CM, Doughty NJ, Goldsmith K, Soon E, Toshner MR, et al. Long-term use of sildenafil in inoperable chronic thromboembolic pulmonary hypertension. Chest. 2008;134(2):229\u201336.","journal-title":"Chest"},{"issue":"4","key":"4069_CR15","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1056\/NEJMoa1209655","volume":"369","author":"H-A Ghofrani","year":"2013","unstructured":"Ghofrani H-A, Gali\u00e8 N, Grimminger F, Gr\u00fcnig E, Humbert M, Jing Z-C, et al. Riociguat for the treatment of pulmonary arterial hypertension. N Engl J Med. 2013;369(4):330\u201340.","journal-title":"N Engl J Med"},{"issue":"1","key":"4069_CR16","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1164\/rccm.200411-1587OC","volume":"172","author":"J Wharton","year":"2005","unstructured":"Wharton J, Strange JW, M\u00f8ller GM, Growcott EJ, Ren X, Franklyn AP, et al. Antiproliferative effects of phosphodiesterase type 5 inhibition in human pulmonary artery cells. Am J Respir Crit Care Med. 2005;172(1):105\u201313.","journal-title":"Am J Respir Crit Care Med"},{"issue":"20","key":"4069_CR17","doi-asserted-by":"publisher","first-page":"2263","DOI":"10.1161\/CIRCULATIONAHA.110.981738","volume":"123","author":"J-P Stasch","year":"2011","unstructured":"Stasch J-P, Pacher P, Evgenov OV. Soluble guanylate cyclase as an emerging therapeutic target in cardiopulmonary disease. Circulation. 2011;123(20):2263\u201373.","journal-title":"Circulation"},{"issue":"1","key":"4069_CR18","first-page":"64","volume":"36","author":"C-H Tsai","year":"2020","unstructured":"Tsai C-H, Wu C-K, Kuo P-H, Hsu H-H, Chen Z-W, Hwang J-J, et al. Riociguat improves pulmonary hemodynamics in patients with inoperable chronic thromboembolic pulmonary hypertension. Acta Cardiol Sin. 2020;36(1):64.","journal-title":"Acta Cardiol Sin"},{"issue":"2","key":"4069_CR19","doi-asserted-by":"publisher","first-page":"125","DOI":"10.2478\/jtim-2022-0027","volume":"10","author":"J Liu","year":"2022","unstructured":"Liu J, Yang P, Tian H, Zhen K, McCabe C, Zhao L, et al. Right ventricle remodeling in chronic thromboembolic pulmonary hypertension. J Transl Intern Med. 2022;10(2):125\u201333.","journal-title":"J Transl Intern Med"},{"key":"4069_CR20","doi-asserted-by":"publisher","first-page":"100579","DOI":"10.1016\/j.ijcha.2020.100579","volume":"29","author":"T Aoki","year":"2020","unstructured":"Aoki T, Sugimura K, Terui Y, Tatebe S, Fukui S, Miura M, et al. Beneficial effects of Riociguat on hemodynamic responses to exercise in CTEPH patients after balloon pulmonary angioplasty\u2013a randomized controlled study. IJC Heart Vasc. 2020;29:100579.","journal-title":"IJC Heart Vasc"}],"container-title":["BMC Pulmonary Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12890-025-04069-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12890-025-04069-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12890-025-04069-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T14:07:29Z","timestamp":1770041249000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12890-025-04069-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,3]]},"references-count":20,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4069"],"URL":"https:\/\/doi.org\/10.1186\/s12890-025-04069-y","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-7275378\/v1","asserted-by":"object"}]},"ISSN":["1471-2466"],"issn-type":[{"value":"1471-2466","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,3]]},"assertion":[{"value":"2 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Joint Chinese University of Hong Kong-New Territories East Cluster Clinical Research Ethics Committee (Ref: 2023.577). Written informed consent to participate in the study was obtained from all participating patients.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written informed consent was obtained from all participating patients for the publication of their details.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"42"}}